DuPont de Nemours, Inc. (DD), based in Wilmington, Delaware, is a top specialty chemical company providing technology-based materials, ingredients, and solutions. Valued at a market cap of $30.4 billion, its operations span the Americas, Indo-Pacific, Europe, and America. DD is likely to announce its Q4 earnings before the market opens on Tuesday, Feb. 4.
Ahead of the event, analysts expect DuPont to report a profit of $0.98 per share, up nearly 12.6% from $0.87 per share reported in the year-ago quarter. Moreover, the company has surpassed Wall Street’s adjusted EPS projections in each of the past four quarters. DD reported adjusted EPS of $1.18 in the previous quarter, exceeding the consensus estimates by 13.5%.
For the year ended in December 2024, analysts expect DuPont to report an adjusted EPS of $3.91, up 12.4% from $3.48 in fiscal 2023.
DD stock has plunged 4.6% over the past year, underperforming the S&P 500 Index’s ($SPX) 21.8% gains and the Materials Select Sector SPDR Fund’s (XLB) marginal fall over the same time frame.
DuPont’s underperformance relative to the market can be attributed to slower-than-expected revenue growth in key sectors like electronics and materials, along with rising raw material costs and supply chain disruptions, which may have pressured profit margins. Additionally, broader market conditions such as economic uncertainty, inflation, and geopolitical risks could have negatively impacted the stock.
On Nov. 5, DD shares surged over 4% following the release of its Q3 earnings. The company reported net sales of $3.2 billion, reflecting a 4.4% year-over-year increase. Adjusted EPS rose 28.3% compared to the previous year, reaching $1.18. Additionally, DD raised its full-year adjusted EPS guidance to $3.90.
The consensus opinion on DD stock is moderately bullish, with an overall “Moderate Buy” rating. Out of the 16 analysts covering the stock, nine recommend “Strong Buy,” one advises “Moderate Buy,” four suggest “Hold,” one advocate “Moderate Sell,” and the remaining has a “Strong Sell” rating.
DD’s mean price target of $99.15 indicates an upswing potential of 36.4% from the current market prices.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. More news from Barchart- This Biotech Penny Stock Is Up 120% This Year. Analysts Think It Can Still Triple From Here in 2025.
- Trump Wants Greenland. Why That Could Be Bad News for Novo Nordisk Stock.
- Upstart Stock Plunged 30% in a Month. Should You Stay Away or Buy UPST on the Dip?
- 3 Under-the-Radar AI Stocks Analysts Are Betting On in 2025
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
